16.16

0.87% 0.14

Pre-market: 16.16

Adma Biologics Inc (ADMA)

Overview News Price History Option Chain Financials Discussions Forecast

Adma Biologics Inc stock is traded at $16.16, with a volume of 3.09M. It is up +0.87% in the last 24 hours and down -7.13% over the past month. ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Previous Close:

$16.02

Open:

$16.2

24h Volume:

3.09M

Relative Volume:

1.08

Market Cap:

$3.82B

Revenue:

$382.81M

Net Income/Loss:

$68.13M

P/E Ratio:

57.71

EPS:

0.28

Net Cash Flow:

$78.82M

1W Performance:

-0.98%

1M Performance:

-7.13%

6M Performance:

+20.96%

1Y Performance:

+222.55%

1-Day Range:

$15.92

$16.50

1-Week Range:

$15.92

$17.32

52-Week Range:

$5.00

$23.64

Adma Biologics Inc Stock (ADMA) Company Profile

Name

Adma Biologics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

(201) 478-5552

Address

C/O ADMA BIOLOGICS, INC., RAMSEY

Employee

624

Twitter

@AdmaBiologics

Next Earnings Date

2024-12-07

Latest SEC Filings

ADMA's Discussions on Twitter

Compare ADMA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADMA Adma Biologics Inc	16.16	3.82B	382.81M	68.13M	78.82M	0.28
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-19-23	Resumed	Raymond James	Strong Buy
Oct-13-22	Initiated	Mizuho	Buy
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight
Jun-04-19	Initiated	Jefferies	Buy
Apr-15-19	Reiterated	H.C. Wainwright	Buy
Feb-07-19	Resumed	H.C. Wainwright	Buy
Dec-11-17	Reiterated	Maxim Group	Buy
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy
May-13-15	Reiterated	Maxim Group	Buy
Dec-08-14	Initiated	Oppenheimer	Outperform
Dec-01-14	Reiterated	Maxim Group	Buy

View All

Adma Biologics Inc Stock (ADMA) Latest News

Jan 21, 2025

Perpetual Ltd Invests $62.30 Million in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat

Jan 21, 2025

ADMA Stock Catapults 275.7% in a Year: How Should You Play the Stock? - MSN

Jan 21, 2025

Jan 20, 2025

Blood Plasma Market Growing at 4.07% CAGR to Hit 42.0 Billion USD by 2032 | Emergent BioSolutions, ADMA - EIN News

Jan 20, 2025

Assenagon Asset Management S.A. Sells 2,882,776 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat

Jan 19, 2025

Jan 18, 2025